Raymond James raises Vera Therapeutics price target on strong launch
Raymond James raised its price target on Vera Therapeutics (NASDAQ:VERA) to $87, citing strong early sales of Trutakna, which generated $10.3M in Q3 2026 revenue, exceeding estimates. The company remains unprofitable but is on track for regulatory submissions. Analysts have mixed price targets, ranging from $34 to $100, with a consensus Strong Buy rating.
How this was made
The 30-second read
Why it matters
The earnings beat and target raise suggest the product is gaining traction, supporting a bullish outlook.
Market read
New earnings data and analyst upgrade provide a fresh catalyst for VERA.
What to watch
Potential competition from Otsuka and the need for weekly dosing could temper growth.
Background
Vera Therapeutics recently launched Trutakna, its first B‑cell modulator for IgAN, and is filing for full approval.
Ticker impact
Raymond James raised its price target to $87 and reported Q3 2026 earnings with $10.3M revenue, beating estimates.
likely upward pressure as the market prices in the higher target and revenue beat
Target raise and better-than-expected sales indicate improved growth outlook, prompting buying interest.
Market effects
Biotech sector may see modest lift as a peer demonstrates successful launch.
U.S. biotech stocks could benefit from the positive earnings signal.
Limited to investors focused on U.S. biotech and specialty pharma.
Counterpoint
Some investors may view the revenue size as still modest and question sustainability.
Key entities
- AnalystRaymond James
Raised price target to $87.
- ProductTrutakna
Biologic therapy generating $10.3M in Q3 revenue.
